The 12 closest competitors and alternatives to AdvanCell Isotopes Pty Ltd among biotech companies — ranked by similarity to what AdvanCell Isotopes Pty Ltd actually does, not by market-cap band.
Subscribe to see AdvanCell Isotopes Pty Ltd’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AdvanCell Isotopes Pty Ltd is an Australian medical-isotope company developing technologies to produce isotopes used in targeted radiopharmaceutical cancer treatments. It serves radiopharmaceutical developers, pharmaceutical companies, and nuclear-medicine providers seeking reliable supplies of therapeutic isotopes.
AdvanCell Isotopes Pty Ltd is a biotech company headquartered in Australia. Its most recent funding round raised $5M in December 2023. Xcout tracks 4 named people at AdvanCell Isotopes Pty Ltd, including Philina Lee (CEO). Xcout recorded 19 job postings from AdvanCell Isotopes Pty Ltd in the last 90 days.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 19 job postings from AdvanCell Isotopes Pty Ltd in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see AdvanCell Isotopes Pty Ltd's hiring signals →
Ranked by semantic similarity — how close each company is to AdvanCell Isotopes Pty Ltd by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Atley Solutions is a global leader in commercial products and services for astatine-related (At-211) radiopharmaceutical development and scalable manufacturing, originating from research at the University of Gothenburg.
Biotechnology
AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.
Pharmaceuticals
Thor Medical produces and supplies alpha-particle emitters used in targeted cancer therapy and radionuclide treatments. The company utilizes a proprietary, environmentally friendly technology to extract radioactive decay products from thorium for medical applications.
Health Care
Fluicell develops precision-engineered biological tissues and single-cell bioprinting technologies for regenerative medicine and drug screening. Using its proprietary platforms, including Nexocyte and Biopixlar, the company creates transplantable tissues to target diseases such as type 1 diabetes and provides advanced tools and screening models for pharmaceutical and academic partners.
Pharmaceuticals
API Co supplies active pharmaceutical ingredients, intermediates, excipients, and nutraceuticals for the healthcare industry.
Similar biotech company
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Biotechnology
ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company based in Garching bei München, Germany. It develops, produces, and globally supplies targeted radiotherapeutic and diagnostic agents for cancer treatment. The company notably secured a major €255 million investment round to further advance its clinical pipeline.
Similar biotech company
Alpha-9 Oncology Inc. is a clinical-stage radiotherapeutic company developing targeted, next-generation radiopharmaceuticals for cancer therapy with operations spanning Boston, Massachusetts and Vancouver, Canada.
Biotechnology
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Similar biotech company
ARTBIO is a biotechnology company developing targeted alpha-particle radioligand therapies for cancer, including treatments intended to selectively deliver radioactive payloads to tumor cells. Its work is aimed at serving oncology patients and healthcare providers treating solid tumors.
Biotechnology
Full-Life Technologies Limited is a fully integrated global radiopharmaceutical company focused on drug development in oncology, headquartered in Shanghai, China, with additional operations in Europe.
Biotechnology
Nuclidium is a precision oncology company headquartered in Basel, Switzerland. It specializes in developing next-generation copper radiotheranostics to provide personalized treatment options for cancer patients at various stages.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AdvanCell Isotopes Pty Ltdand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →